Literature DB >> 12825835

P2Y6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosis.

Seong G Kim1, Zhan-Guo Gao, Kelly A Soltysiak, Tong-Shin Chang, Chaya Brodie, Kenneth A Jacobson.   

Abstract

1. We recently reported that the activation by UDP of rat P2Y6 nucleotide receptors expressed in 1321N1 astrocytoma cells protected them from TNFalpha-induced apoptosis by suppressing activation of caspase 3 and 8. This study aims to characterize the involvement of intracellular signaling pathways, including kinases involved in the antiapoptotic effect of UDP. 2. Cell death was induced in 1321N1 astrocytoma cells permanently expressing the rat P2Y6 receptor by exposure to TNFalpha in the presence of cycloheximide. The apoptotic fraction was analyzed using flow cytometry. 3. The activation of P2Y6 receptors by UDP both protected the astrocytes from TNF-alpha induced apoptosis and activated protein kinase C (PKC) isotypes. The phorbol ester PMA also activated PKC and protected the cells from TNFalpha-induced cell death. The alpha- and epsilon-isotypes of PKC were both activated in a persistent fashion upon 5-min exposure to either UDP (10 microM) or the phorbol ester PMA (100 nM). The PKCzeta isotype was markedly activated upon UDP treatment. 4. The addition of PKC inhibitors, GF109203X or Gö6976, partially antagonized the protective effect of UDP and reduced the UDP-induced phosphorylation of extracellular signal-regulated protein kinases (Erk). The inhibitors of Erk, PD98,059 or U0126, antagonized UDP-induced protection. 5. The antiapoptotic protein, Akt, was not affected by P2Y6 receptor activation. Incubation of the astrocytes with calcium modifiers BAPTA-AM or dantrolene, did not affect the UDP-induced protection from apoptosis. 6. The addition of phospholipase C (PLC) inhibitors, D609 or U73122, partially antagonized both UDP-induced protection and PKC activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825835      PMCID: PMC3140713          DOI: 10.1023/a:1023696806609

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  58 in total

1.  Life-or-death decisions.

Authors:  J M Kyriakis
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

2.  UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y(6) receptors.

Authors:  Mingyan Hou; T Kendall Harden; Cynthia M Kuhn; Bo Baldetorp; Eduardo Lazarowski; William Pendergast; Sebastian Möller; Lars Edvinsson; David Erlinge
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-02       Impact factor: 4.733

3.  Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release.

Authors:  Erika M Gibson; Elizabeth S Henson; Neil Haney; Jacylyn Villanueva; Spencer B Gibson
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

4.  Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling.

Authors:  E De Smaele; F Zazzeroni; S Papa; D U Nguyen; R Jin; J Jones; R Cong; G Franzoso
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

5.  Inhibition of JNK activation through NF-kappaB target genes.

Authors:  G Tang; Y Minemoto; B Dibling; N H Purcell; Z Li; M Karin; A Lin
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

6.  Mechanisms of the induction of apoptosis in human hepatoma cells by tumour necrosis factor-alpha.

Authors:  J Li; R Zheng; J Li; Z Wang
Journal:  Cell Biol Int       Date:  2001       Impact factor: 3.612

7.  Akt protects mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis through NK-kappa B activation.

Authors:  E Hatano; D A Brenner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-12       Impact factor: 4.052

8.  The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.

Authors:  D Toullec; P Pianetti; H Coste; P Bellevergue; T Grand-Perret; M Ajakane; V Baudet; P Boissin; E Boursier; F Loriolle
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

9.  Three distinct cell phenotypes of induced-TNF cytotoxicity and their relationship to apoptosis.

Authors:  K M Woods; S K Chapes
Journal:  J Leukoc Biol       Date:  1993-01       Impact factor: 4.962

10.  Tumor necrosis factor alpha-induced apoptosis in astrocytes is prevented by the activation of P2Y6, but not P2Y4 nucleotide receptors.

Authors:  Seong G Kim; Kelly A Soltysiak; Zhan-Guo Gao; Tong-Shin Chang; Eunju Chung; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2003-03-15       Impact factor: 5.858

View more
  23 in total

1.  Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.

Authors:  Hiroshi Maruoka; Matthew O Barrett; Hyojin Ko; Dilip K Tosh; Artem Melman; Lauren E Burianek; Ramachandran Balasubramanian; Barkin Berk; Stefano Costanzi; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

Review 2.  Supportive or detrimental roles of P2Y receptors in brain pathology?--The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies.

Authors:  Daniel Förster; Georg Reiser
Journal:  Purinergic Signal       Date:  2015-09-25       Impact factor: 3.765

3.  Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells.

Authors:  Philip R Lee; Jonathan E Cohen; Elisabetta A Tendi; Robert Farrer; George H DE Vries; Kevin G Becker; R Douglas Fields
Journal:  Neuron Glia Biol       Date:  2004-05

4.  Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation.

Authors:  Liaman K Mamedova; Ruibo Wang; Pedro Besada; Bruce T Liang; Kenneth A Jacobson
Journal:  Pharmacol Res       Date:  2008-08-30       Impact factor: 7.658

Review 5.  Agonists and antagonists for P2 receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Bhalchandra V Joshi; Pedro Besada; Dae Hong Shin; Hyojin Ko; Andrei A Ivanov; Liaman Mamedova
Journal:  Novartis Found Symp       Date:  2006

6.  Pyrimidine Nucleotides Containing a (S)-Methanocarba Ring as P2Y6 Receptor Agonists.

Authors:  Kiran S Toti; Shanu Jain; Antonella Ciancetta; Ramachandran Balasubramanian; Saibal Chakraborty; Ryan Surujdin; Zhen-Dan Shi; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2017-09-06       Impact factor: 3.597

7.  Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors.

Authors:  Liaman K Mamedova; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2006-08-28       Impact factor: 5.858

Review 8.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

9.  Purinergic receptor antagonism prevents cold preservation-induced cell death independent of cellular ATP levels.

Authors:  Christopher D Anderson; Janene Pierce; Ian B Nicoud; Andrey E Belous; Christopher M Jones; Ravi S Chari
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

10.  Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors.

Authors:  Liaman K Mamedova; Bhalchandra V Joshi; Zhan-Guo Gao; Ivar von Kügelgen; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-05-01       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.